Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has earned an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $12.00.

Several brokerages have weighed in on REPL. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and upped their price target for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st.

Replimune Group Stock Performance

Replimune Group stock opened at $12.60 on Friday. The firm’s fifty day moving average price is $12.96 and its 200-day moving average price is $9.16. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The stock has a market cap of $1.18 billion, a P/E ratio of -4.00 and a beta of 0.94. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $16.33.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, equities research analysts expect that Replimune Group will post -2.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider owned 224,215 shares of the company’s stock, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of Replimune Group stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the sale, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. The trade was a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 79,124 shares of company stock worth $1,038,364. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Replimune Group during the second quarter valued at $99,171,000. Montanova Capital LLC increased its holdings in Replimune Group by 4.0% in the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after buying an additional 168,000 shares in the last quarter. Erste Asset Management GmbH increased its holdings in Replimune Group by 30.1% in the 4th quarter. Erste Asset Management GmbH now owns 2,120,000 shares of the company’s stock worth $20,619,000 after buying an additional 490,000 shares in the last quarter. Opaleye Management Inc. purchased a new position in Replimune Group in the 2nd quarter worth about $15,332,000. Finally, Commodore Capital LP purchased a new position in Replimune Group in the 4th quarter worth about $13,851,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.